The Brazilian healthcare market is one of the largest and most promising in Latin America. With a population of over 200 million people and growing demand for medical innovation, Brazil represents a significant opportunity for international manufacturers of healthcare products and medical devices.

However, to operate legally in the country, it is essential to understand the health product registration process with the Brazilian Health Regulatory Agency (ANVISA), the government body responsible for regulating and overseeing these products nationwide.

What Is ANVISA?

ANVISA is a regulatory agency affiliated with Brazil’s Ministry of Health. It is responsible for evaluating the safety, efficacy, and quality of products intended for healthcare use. Its responsibilities include the health regulation of medicines, medical devices, hospital equipment, cosmetics, sanitation products, and various other products.

Before a product can be marketed in Brazil, its regulatory classification must be determined and, in most cases, the applicable ANVISA authorization must be obtained.

Classification of Healthcare Products

In Brazil, medical devices are classified according to the level of risk they pose to patients and users. This classification directly affects the complexity and timeline of the regulatory process.

In general, medical devices fall into four risk classes:

• Class I – Low Risk
• Class II – Medium Risk
• Class III – High Risk
• Class IV – Highest Risk

Lower-risk products generally follow simpler regulatory pathways, while more complex devices require more detailed technical assessments and additional documentation.

Steps in the Registration Process

Although requirements vary depending on the type of product, the process typically involves the following steps.

1. Determining the Regulatory Classification

The first step is to correctly identify the product category and risk class under Brazilian regulations. This determination is essential for establishing the required documentation and procedures.

2. Establishing Regulatory Compliance in Brazil

To market medical products in Brazil, a company must be legally established in the country and hold the applicable ANVISA authorizations. In many cases, international manufacturers work through local distributors or regulatory partners.

3. Preparing the Technical Documentation

Documentation may include:

• Technical product descriptions;
• Instructions for use;
• Applicable studies and test reports;
• International certificates;
• Manufacturing information;
• Safety and performance data.

The quality and organization of this documentation can significantly affect the progress of the regulatory process.

4. Submission to ANVISA

Once the documentation is prepared, the application is submitted electronically to ANVISA for technical review.

Depending on the product category, the applicable pathway may involve:

• Notification;
• Registration through a simplified filing process (cadastro);
• Full sanitary registration.

5. Review and Approval

ANVISA conducts the technical assessment and may request clarifications or additional documentation during the process. Once the applicable requirements have been met and authorization is granted, the product may be marketed in Brazil, subject to all other applicable requirements.

How Long Does the Process Take?

Timelines vary considerably depending on the product category, risk classification, and complexity of the supporting documentation.

Low-risk products often follow faster regulatory pathways, while more complex medical devices may require more extensive assessments.

Appropriate regulatory planning can help reduce delays, avoid rework, and improve the efficiency of the process.

The Importance of a Local Partner

Brazil’s regulatory environment has specific requirements and demands familiarity with technical standards, documentation requirements, and administrative procedures.

For this reason, many international companies choose to work with specialized local partners who can provide support ranging from regulatory strategy to commercial distribution.

Practical experience with ANVISA and knowledge of the Brazilian healthcare market can help make the process more efficient, reliable, and predictable.

Conclusion

Registering a new healthcare product or medical device in Brazil is a fundamental step for companies seeking to enter one of Latin America’s most significant markets.

Although the regulatory process requires technical expertise and careful planning, working with experienced partners and obtaining specialized guidance can facilitate entry into the Brazilian market.

At EMDUTOS, we work alongside international manufacturers, providing strategic, regulatory, and commercial support to help bring healthcare technologies and products to Brazil.